Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Mustang Bio’s stock leapt more than 400% before settling down, on the news that its gene therapy cured eight infants with “bubble boy” syndrome.
In this week's EuroBiotech Report, GSK plans R&D cuts, Genfit gets breakthrough status and Kiadis pens deal to buy CytoSen.
Mitotech – a biotech specializing in targeting mitochondria – is moving into late stage of clinical development in Dry Eye Disease.
In our EuroBiotech roundup this week, Hookipa prices IPO, Affimed eyes end of clinical hold and Cassiopea posts hair loss data.
The breakthrough tag comes as Genfit gears up to start a phase 3 trial in the indication later in the year.
The drug ACT017 from Acticor targets GPVI, a platelet protein that's critical for blood clot formation but doesn’t affect the regulation of bleeding.
The appointment gives Obsidian a full-time CEO following a period in which Michael Gilman helmed the biotech while also running Arrakis Therapeutics.
Biotech vet Michael Gilman stepped down as Obsidian Therapeutics' CEO and buckled in at Arrakis as the company advances four RNA-targeting drugs.
Talaris Therapeutics raised $100 million to move its cell therapy for kidney transplant patients into phase 3.
Scientists from the Children’s Hospital of Philadelphia and UPenn have used CRISPR gene editing to prevent a lung disease in mice before birth.
Nocion is working on positively charged molecules that silence nociceptors—the neurons that send pain or itch signals—without affecting other neurons.
